Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti–tumor necrosis factor therapy among patients with inflammatory bowel disease
American Journal of Clinical Pathology · 2023
DOI: 10.1093/ajcp/aqad036 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Regina M DelBaugh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, US. Hauptthemen laut MEDLINE: HLA-DQ Antigens, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objectives
The HLA-DQA1*05 variant (rs2097432) is associated with increased risk of immunogenicity to tumor necrosis factor antagonists, with subsequent resistance to therapy in patients with inflammatory bowel disease. Identification of these patients would optimize personalized therapeutic selection.
Methods
Genomic DNA was extracted from 80 deidentified samples in an unselected patient population with an unknown rs2097432 genotype. Split sample analysis was performed using a reference laboratory. Primer probes for a TaqMan quantitative polymerase chain reaction (qPCR) assay (Thermo Fisher Scientific) were custom designed. Synthesized genomic-block fragments were used as controls. All qPCR reactions were performed using a TaqMan GTXpress Master Mix (Thermo Fisher Scientific) on the Applied Biosystems 7500 system under fast cycling conditions.
Results
Of 80 samples, 50% were wild-type reference genotypes, 22.5% were heterozygous, and 27.5% were homozygous variant calls, comparable to population data. Split analysis samples between 2 independent laboratories were 100% concordant. The detection limit tested across genomic-block controls processed in duplicate was reproducible on sample input from 10 ng titrated down to 1.25 ng across 2 independent runs. Further, analytical specificity assessed with previous wild-type reference and homozygous variant DNA spiked into genomic-block controls produced appropriate heterozygous genotypes.
Conclusions
Here we present validation of a lab-developed test for a rapid HLA-DQA1*05 (rs2097432) pharmacogenomics assay targeting a hotspot identified by genome-wide association studies. Targeted genotyping employed here will allow for expeditious personalized therapeutic selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, US.
- Laboratory for Clinical Genomics and Advanced Technology, Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, US.
- Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, US.
- Department of Medicine, The Audrey and Theodore Geisel School of Medicine at Dartmouth College, Hanover, NH, US.
- Department of Pathology and Laboratory Medicine, The Audrey and Theodore Geisel School of Medicine at Dartmouth College, Hanover, NH, US.
ORCID-Profile: Regina M DelBaugh, Corey A Siegel
Zitieren
APA
DelBaugh, R. M., Cook, L. J., Siegel, C. A., Tsongalis, G. J., & Khan, W. A. (2023). Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti–tumor necrosis factor therapy among patients with inflammatory bowel disease. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad036
Vancouver
DelBaugh RM, Cook LJ, Siegel CA, Tsongalis GJ, Khan WA. Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti–tumor necrosis factor therapy among patients with inflammatory bowel disease. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqad036
BibTeX
@article{DelBaugh2023,
author = {DelBaugh, Regina M and Cook, Leanne J and Siegel, Corey A and Tsongalis, Gregory J and Khan, Wahab A},
title = {Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti–tumor necrosis factor therapy among patients with inflammatory bowel disease},
journal = {American Journal of Clinical Pathology},
year = {2023},
doi = {10.1093/ajcp/aqad036}
}
EUVIMED